SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Allogeneic, Autologous, BCMA, CAR-T, CD19

January 05, 2024

Poseida Publishes Future Milestones for 2024; Company Considering Entrance in Autoimmune Diseases; Adaptimmune to Pursue Lete-cel Approval By 2026

Here is a brief preview of this blast: On Thursday, January 4, Poseida provided business updates and future milestones for its allogeneic cell therapy programs (press release). On the same day, Adaptimmune disclosed its plans for its sarcoma pipeline (press release), disclosing its plans to continue developing lete-cel (NY-ESO-1 TCR-T) and to seek approval for its second asset, with an expected US launch in 2026.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.